Vizsgálati helyszín
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo 01317-001, BrazíliaMég nincs intézményhez kötve
- 8futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 11 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis6 vizsgálat
- 2. fázis5 vizsgálat
- Állapot
- Fut, nem toboroz4 vizsgálat
- Toboroz4 vizsgálat
- Lezárult3 vizsgálat
- Fő szponzor
- Hoffmann-La Roche10 vizsgálat
- Population Health Research Institute1 vizsgálat
Futó vizsgálatok
Toboroz
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
NCT04680442· 2. fázis· Population Health Research Institute· Forrás
Contact: Nathalia Santos
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· 3. fázis· Hoffmann-La Roche· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek